Cargando…

Factors Associated with Indacaterol Response in Tuberculosis-Destroyed Lung with Airflow Limitation

BACKGROUND: Pulmonary tuberculosis can result in anatomical sequelae, and cause airflow limitation. However, there are no treatment guidelines for patients with a tuberculosis-destroyed lung. Recently, indacaterol effectiveness in chronic obstructive pulmonary disease (COPD) patients with Tuberculos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Tae Hoon, Rhee, Chin Kook, Oh, Yeon-Mok
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Academy of Tuberculosis and Respiratory Diseases 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304328/ https://www.ncbi.nlm.nih.gov/pubmed/30574688 http://dx.doi.org/10.4046/trd.2018.0050

Ejemplares similares

Effects of inhaler therapy on mortality in patients with tuberculous destroyed lung and airflow limitation
por: Kim, Ho Cheol, et al.
Publicado: (2019)

Inhaled indacaterol for the treatment of COPD patients with destroyed lung by tuberculosis and moderate-to-severe airflow limitation: results from the randomized INFINITY study
por: Kim, Cheong-Ju, et al.
Publicado: (2017)

Effect of Airflow Limitation on Acute Exacerbations in Patients with Destroyed Lungs by Tuberculosis
por: Kim, Soo Jung, et al.
Publicado: (2015)

Effect of tiotropium inhaler use on mortality in patients with tuberculous destroyed lung: based on linkage between hospital and nationwide health insurance claims data in South Korea
por: Kim, Ho Cheol, et al.
Publicado: (2019)

The Impact of Smoking on Airflow Limitation in Subjects with History of Asthma and Inactive Tuberculosis
por: Kim, Hyun Jung, et al.
Publicado: (2015)

Hand Grip Strength and Likelihood of Moderate-to-Severe Airflow Limitation in the General Population
por: Kim, Sunyoung, et al.
Publicado: (2022)

Effect of Indacaterol on Cough and Phlegm in Chronic Obstructive Pulmonary Disease Patients: A Meta-Analysis of Five Randomized Controlled Trials
por: Park, Jinkyeong, et al.
Publicado: (2015)

Safety and Effectiveness of Indacaterol in Chronic Obstructive Pulmonary Disease Patients in South Korea
por: Yum, Ho-Kee, et al.
Publicado: (2017)

Identification of subtypes in subjects with mild-to-moderate airflow limitation and its clinical and socioeconomic implications
por: Lee, Jin Hwa, et al.
Publicado: (2017)

Systematic review comparing LABA, olodaterol, and indacaterol: limitations
por: Donohue, James F
Publicado: (2014)

Incidence and risk factors of postoperative complications in patients with tuberculosis-destroyed lung
por: Ruan, Hongyun, et al.
Publicado: (2021)

Validity and Reliability of CAT and Dyspnea-12 in Bronchiectasis and Tuberculous Destroyed Lung
por: Lee, Bo Young, et al.
Publicado: (2012)

Impact of BMI on exacerbation and medical care expenses in subjects with mild to moderate airflow obstruction
por: Jo, Yong Suk, et al.
Publicado: (2018)

Direct Switch from Tiotropium to Indacaterol/Glycopyrronium in Chronic Obstructive Pulmonary Disease Patients in Korea
por: Lee, Sang Haak, et al.
Publicado: (2021)

Association of incidental emphysema with annual lung function decline and future development of airflow limitation
por: Koo, Hyeon-Kyoung, et al.
Publicado: (2016)

Lung matrix metalloproteinase-9 correlates with cigarette smoking and obstruction of airflow.
por: Kang, Min Jong, et al.
Publicado: (2003)

Computed Tomography Structural Lung Changes in Discordant Airflow Limitation
por: Hoesein, Firdaus A. A. Mohamed, et al.
Publicado: (2013)

Cut-off value of FEV(1)/FEV(6) to determine airflow limitation using handheld spirometry in subjects with risk of chronic obstructive pulmonary disease
por: Hwang, Yong Il, et al.
Publicado: (2021)

Destroy, what destroys you
por: Luu, Khang, et al.
Publicado: (2019)

Indacaterol: a comprehensive review
por: Rossi, Andrea, et al.
Publicado: (2013)

Predicting Mortality in Patients with Tuberculous Destroyed Lung Receiving Mechanical Ventilation
por: Kim, Won-Young, et al.
Publicado: (2018)

Efficacy and safety of indacaterol/glycopyrronium fixed-dose combination in mild-to-moderate COPD patients symptomatic on tiotropium in Korea: study protocol for a randomized controlled trial
por: Rhee, Chin Kook, et al.
Publicado: (2017)

Comparison of Clinical Efficacy and Safety between Indacaterol and Tiotropium in COPD: Meta-Analysis of Randomized Controlled Trials
por: Kim, Jung Soo, et al.
Publicado: (2015)

Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD—a randomised controlled study
por: Salomon, Joerg, et al.
Publicado: (2017)

Factors affecting the development of airflow limitation among South Korean smokers
por: Kim, Youngmee, et al.
Publicado: (2019)

Combination therapy for airflow limitation in COPD
por: Ghanei, Mostafa, et al.
Publicado: (2012)

Summary of the Chronic Obstructive Pulmonary Disease Clinical Practice Guideline Revised in 2014 by the Korean Academy of Tuberculosis and Respiratory Disease
por: Yoon, Hyoung Kyu, et al.
Publicado: (2017)

Association between airflow limitation and prognosis in patients with chronic pulmonary aspergillosis
por: Lee, Myoung Kyu, et al.
Publicado: (2021)

Safety of indacaterol in the treatment of patients with COPD
por: Donohue, James F, et al.
Publicado: (2011)

Effects of long-term bronchodilators in bronchiectasis patients with airflow limitation based on bronchodilator response at baseline
por: Jeong, Ho Jung, et al.
Publicado: (2016)

Long-term follow-up of tuberculosis-destroyed lung patients after surgical treatment
por: Ruan, Hongyun, et al.
Publicado: (2022)

Treatment response among asthmatic patients with and without reversible airflow limitations
por: Albanna, Amr S., et al.
Publicado: (2021)

A diffuse lung emphysema, severe pulmonary hypertension and lack of airflow limitation
por: Faure, Morgane, et al.
Publicado: (2017)

Airflow Limitation Increases Lung Cancer Risk in Smokers: The Lifelines Cohort Study
por: Du, Yihui, et al.
Publicado: (2022)

Impact of airflow limitation in chronic heart failure
por: Bektas, S., et al.
Publicado: (2017)

Risk factors for persistent airflow limitation: Analysis of 306 patients with asthma
por: Wang, Lingcheng, et al.
Publicado: (2014)

Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study
por: Vincken, Walter, et al.
Publicado: (2014)

Correlation of lung vibration and airflow
por: Jean, S, et al.
Publicado: (2007)

Relationship between FEV1 and Cardiovascular Risk Factors in General Population without Airflow Limitation
por: Lee, Jeong Hyeon, et al.
Publicado: (2016)

Risk of short- and long-term pulmonary complications should be determined before surgery for tuberculosis-destroyed lung
por: Park, Dong Won, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_j8f38phnie5sk72fmmmupc7kp1